Who We Are


NanoValent Pharmaceuticals, Inc. (NVP), founded in 2006, is a privately-held company with headquarters in Bozeman (MT) collaborating with Children’s Hospital Los Angeles (CHLA) as well as other US academic partners to develop novel therapeutic options with enhanced target and delivery characteristics. NanoValent possesses a highly experienced core management team with a proven track record of success, supported by a strong clinical and operational support group.


NVP has so far developed three HPLN (Hybrid Polymerized Liposomal Nanoparticle) based TNS (Targeted Nanosphere) candidates in oncology: NV101, NV102 and our lead NV103.

These first NVP candidates (NV101 (Doxorubicin-anti-CD99), NV102 (Doxorubicin-anti-CD19) and NV103 (Irinotecan-anti-CD99) are approaching IND status and validating programs in Ewing sarcoma (with NV101 and NV103) and GBM (Glioblastoma with NV103) are underway.

A further program in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is also envisaged with NV102.

In addition NVP has developed a  modified HPLN structure specifically designed for optimising nucleic acid based therapy delivery. Also, with Boston University the highly novel NV201, a fibrin targeted, PSM (Polymerized Shell Microbubble) ultrasound activated microsphere (TMS) shows early promise in diagnosing and treating surgical adhesions.

Overall, our technology promises to enables significant enhancement of the performance of therapeutic agents. For example, NV102 increases tumor-killing efficacy 10-12 fold in vitro, compared to untargeted HPLN loaded with Doxorubicin and almost 40 fold versus conventional Doxorubicin. With NV101 the enhancement seen has been even greater, 40 fold versus commercially available Doxo-liposomes and 80 fold versus Doxorubicin. We are already seeing similar, perhaps greater, potential of enhanced power and control in NV103 versus already approved benchmark products, and have therefore decided to make this our leading candidate. Once we achieve basic clinical validation in NV103 NanoValent will rapidly progress as a company able to apply our IP to various challenges, both in adult oncology and beyond.


Timothy Enns

Management Consultant

Mr Enns is a Management Consultant and Board member of NanoValent. Mr. Enns has over 30 years experience in senior leadership roles within various Pharmaceutical and Biotechnology companies including KineMed Inc, Astex Pharmaceuticals, Inc (now Otsuka) and Sequus Pharmaceuticals. Mr. Enns management roles have included Business Development, Corporate Communications and Investor Relations, Marketing and Sales. His prior experience includes most aspects of cancer therapeutic commercialization from start up through launch and partnering. Prior to Sequus he held senior positions at Trilex, Syncor, MGI Pharma and Upjohn. He has a BS in Nutritional Science & Biochemistry from UC Davis.

Jon Nagy, PhD

Chief Scientific Officer and President

Dr. Nagy is co-founder of NanoValent and received his PhD in synthetic organic chemistry from Iowa State University in 1983, and completed doctoral training at UC Berkeley. In 1990, Dr. Nagy joined Lawrence Berkeley National Laboratory where he generated seven issued patents and 15 scientific publications, including a paper in Science related to polymer films and nanoparticles. In 1999, Dr. Nagy joined LigoCyte Pharmaceuticals as Director of Chemistry and Nanoparticle research. He is now a full time member of NanoValent.

Timothy Triche MD, PhD

Chief Medical Officer

Dr. Triche is co-founder of NanoValent and is board certified in pathology and is on the staff of Children’s Hospital Los Angeles and a faculty at the University of Southern California. His expertise centers on the field of tumor cell biology. Dr. Triche has been a principle and founder in several publicly traded companies including co-founder of OncorMed, which was sold to Gene Logic (GLGC).

Mark Lewis

International Chief Operating Officer

Mr. Lewis has 35 years international experience in the pharmaceutical industry; 25 years as an executive with companies including Amersham International (now part of GE), Farmitalia (now Pfizer), Chiron (now Novartis), Groupe Servier, Ascalon and SuperGen (now Otsuka) in various senior commercial and operational roles and 10 years as a management consultant (including Quintiles, Hill & Knowlton) for a spectrum of pharmaceutical and biotechnology clients. With an honors degree in biochemistry and secondary business qualifications, Mr. Lewis has an extensive background in strategic marketing, project management, business development, medical affairs and operations gained in several therapeutic areas but primarily oncology.

Clinical & Operational Collaborators

We can disclose this on request.

Advisory Board

In development.

Company Financing

NanoValent has progressed so far thanks to various NIH, NCI and NSF grants for oncology, surgical, imaging and vaccine projects, founder investment and its first external seed investment during 2017. NanoValent is now seeking further external private investment to enable pre-IND activities and then once an IND is achieved will seek further funding to enable a clinical POC (proof of concept) phase.

Intellectual Property

NanoValent has a strong and extensive IP asset portfolio, covering its various development activities. We would be pleased to share this on request.

Company News

NanoValent appoints Timothy Enns as Chief Executive Officer, January 11, 2017Read More

NanoValent announces CHLA agreement and completion of First Wave of Financing, October 10, 2017Read More

NanoValent announces new SBIR funding awards, October 1, 2018Read More

NanoValent announces key US patent award, August 20, 2019Read More

NanoValent’s Tim Triche interviewed in OncoZine, August 2021Read More